Is Ardent Health (ARDT) Cheap As UT Tyler Expansion Lifts Its Long Term Outlook?
Ardent Health (ARDT) is back in focus after UT Health East Texas expanded specialty care into the new UT Tyler School of Medicine Building, uniting patient services with physician training in one regional hub.
For context, Ardent Health’s share price is US$10.76, with the stock easing over the past week but showing a 90 day share price return of 23.96% and a year to date share price return of 24.54%, even though the 1 year total shareholder return is down 16.33%.
Spot opportunities in hospital and care providers following Ardent Health's East Texas expansion by scanning our hand picked list of solid balance sheet and fundamentals (53 results).Ardent Health’s East Texas push has arrived alongside a share price near US$10.76 and a wide gap between current trading levels and some intrinsic value estimates. So where does fair value really sit in that spread?
Most Popular Narrative: 13.9% Undervalued
The most followed narrative for Ardent Health puts fair value at $12.50, above the recent $10.76 share price, and frames the current gap through the lens of earnings power, margins, and discount rate assumptions.
The analysts have a consensus price target of $12.5 for Ardent Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $10.0.
Analysts are sketching a detailed path for Ardent Health that blends measured revenue growth with firmer margins and a higher future earnings base. Curious which specific profit and valuation assumptions have to line up to reach that $12.50 fair value and beyond?
Result: Fair Value of $12.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Ardent Health’s story could change quickly if regulatory shifts affect Medicaid funding or if payer denials and reimbursement disputes once again pressure revenue and margins.
Find out about the key risks to this Ardent Health narrative.
Another View on Ardent Health’s Valuation
The analyst narrative points to Ardent Health trading below a fair value of $12.50, which suggests the stock is 13.9% undervalued versus the recent $10.76 share price. Our discounted cash flow model presents a very different view and prices Ardent Health’s future cash flows at just $3.67 per share, which appears overvalued compared with where the stock trades today. Which version of fair value do you trust when the gap is this wide?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ardent Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With Ardent Health pulling in both concerns and optimism, it makes sense to move quickly and test the numbers yourself, including the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Ardent Health?
If you stop with Ardent Health, you miss a wider set of opportunities. Use the Simply Wall St Screener to compare different return profiles, risks, and balance sheets.
- Target potential value opportunities by scanning a curated 53 high quality undervalued stocks that blend robust fundamentals with pricing that may appeal to patient investors.
- Prioritise resilience by reviewing a 79 resilient stocks with low risk scores that focus on steadier financial profiles and lower overall risk scores.
- Spot future contenders early by checking a 21 high quality undiscovered gems that capture strong fundamentals before they are widely followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com